Results 181 to 190 of about 51,427 (307)

Completion of the Icatibant Outcome Survey and What We Learned

open access: yes
Clinical &Experimental Allergy, EarlyView.
Laurence Bouillet   +8 more
wiley   +1 more source

Garadacimab for the long‐term prophylaxis of hereditary angioedema

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Hereditary angioedema (HAE), a rare and debilitating disease characterized by recurrent and spontaneous attacks of tissue swelling, has a high unmet therapeutic need, with many patients experiencing insufficient disease control with current prophylactic treatments.
Emel Aygören‐Pürsün   +5 more
wiley   +1 more source

Sperm whale demographics in the Gulf of Alaska and Bering Sea/Aleutian Islands: An overlooked female habitat. [PDF]

open access: yesPLoS One
Posdaljian N   +6 more
europepmc   +1 more source

Unusual mortality of Tufted puffins (Fratercula cirrhata) in the eastern Bering Sea. [PDF]

open access: yesPLoS One, 2019
Jones T   +7 more
europepmc   +1 more source

An assessment of climate change vulnerability for Important Bird Areas in the Bering Sea and Aleutian Arc. [PDF]

open access: yesPLoS One, 2019
Smith MA   +5 more
europepmc   +1 more source

Effects of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes at Risk of Liver Fibrosis

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The fibrosis‐4 (FIB‐4) score is used to identify risk of advanced liver fibrosis. This post hoc analysis investigated its prognostic value for cardiovascular (CV) outcomes and its relevance to the effects of dapagliflozin. Materials and Methods DECLARE‐TIMI 58 was a randomised, placebo‐controlled phase 3 trial investigating dapagliflozin ...
Jan Oscarsson   +12 more
wiley   +1 more source

Effects of Vicadrostat/Empagliflozin in People With Chronic Kidney Disease: Metabolic Subgroup Analyses

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims In a phase 2 trial, the efficacy and safety of the highly selective aldosterone synthase inhibitor vicadrostat, alone or with empagliflozin, were investigated in people with chronic kidney disease (CKD) with or without type 2 diabetes (T2D). Materials and Methods Adults (n = 586) with CKD (estimated glomerular filtration rate [eGFR] 30 to
David Z. I. Cherney   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy